WHO Director-General declares mpox outbreak a public health emergency

According to the International Health Regulations (2005) (IHR), WHO Director-General Dr. Tedros Adhanom Ghebreyesus has determined that the outbreak of mpox in the Democratic Republic of the Congo (DRC) and an increasing number of African countries qualifies as a public health emergency of international concern (PHEIC).

On the recommendation of an independent expert panel called the IHR Emergency Committee, which convened earlier in the day to examine data submitted by WHO and affected country experts, Dr. Tedros made his announcement. The Committee notified the Director-General that it believed the mpox outbreak to be a PHEIC, having the potential to spread to other African nations as well as possibly beyond.

The Director-General shall distribute the Committee’s meeting report and, acting upon the Committee’s guidance, make interim recommendations to nations.

“The development of a novel clade of mpox, its rapid dissemination in eastern DRC, and the reporting of cases in multiple neighboring countries are quite concerning,” Dr. Tedros said in declaring the PHEIC. In addition to additional mpox clade epidemics in the Democratic Republic of the Congo and other African nations, it is evident that a concerted international response is required to contain these outbreaks and save lives.

“Significant efforts are already underway in close coordination with communities and governments, with our country teams working on the frontlines to help reinforce measures to limit mpox,” stated Dr. Matshidiso Moeti, Regional Director of WHO for Africa. Along with the

“The current outbreak of mpox in parts of Africa, together with the development of a new sexually transmissible strain of the monkeypox virus, is an emergency, not only for Africa but for the entire planet,” stated committee chair Professor Dimie Ogoina. Originating in Africa, mpox was ignored there until 2022, when it spread over the world. It is time to take urgent action to stop history from happening again.”

This PHEIC determination for mpox is the second in the last two years. Mpox, first reported in humans in the Democratic Republic of the Congo in 1970, is caused by an orthopoxvirus. It is believed that the illness is endemic to nations in central and western Africa.

The rapid sexual transmission of the multi-country mpox outbreak led to its classification as a PHEIC in July 2022.

For almost a decade, the Democratic Republic of Congo has been the source of reports of mpox, with an annual increase in cases observed throughout that time. The number of cases recorded climbed dramatically the previous year, and as of yet, this year’s tally of almost 15,600 cases and 537 deaths has surpassed that of the previous year.

One of the main reasons for the PHEIC declaration was the appearance and rapid spread of clade 1b, a novel virus strain that appeared to be mostly transmitted through sexual networks and was detected in neighboring countries last year. This strain is extremely alarming.

Within the

Several outbreaks of different clades of mpox have occurred in different countries, with different modes of transmission and different levels of risk.

The two vaccines currently in use for mpox are recommended by WHO’s Strategic Advisory Group of Experts on Immunization and are also approved by WHO-listed national regulatory authorities, as well as by individual countries including Nigeria and the DRC.

Last week, the Director-General triggered the process for emergency use listing for mpox vaccines, which will accelerate vaccine access for lower-income countries that have not yet issued their own national regulatory approval. Emergency Use Listing also enables partners, including Gavi and UNICEF, to procure vaccines for distribution.

WHO is working with countries and vaccine manufacturers on potential vaccine donations and coordinating with partners through the interim Medical Countermeasures Network to facilitate equitable access to vaccines, therapeutics, diagnostics, and other tools.

WHO anticipates an immediate funding requirement of an initial US$15 million to support surveillance, preparedness, and response activities. A needs assessment is being undertaken across the three levels of the organization.

To allow for an immediate scale-up, WHO has released US$ 1.45 million from the WHO Contingency Fund for Emergencies and may need to release more in the coming days. The organization appeals to donors to fund the full extent of the needs of the MPOX response.

Monkeypox Virus Symptoms and Treatment Everything You Need to Know

Introduction to Monkeypox Virus

Monkeypox virus, a member of the Orthopoxvirus genus within the Poxviridae family, was first identified in laboratory monkeys in 1958, hence the name “monkeypox.” However, it primarily infects rodents and other non-human primates in certain regions, particularly in Central and West African countries. The first human case of monkeypox was reported in 1970 in the Democratic Republic of Congo, amidst efforts to eliminate smallpox. The virus has been the subject of increasing concern due to the sporadic outbreaks occurring in various countries.

The transmission of monkeypox virus to humans typically occurs through direct contact with the blood, bodily fluids, or cutaneous or mucosal lesions of infected animals. Secondary, human-to-human transmission can happen through respiratory droplets, direct contact with body fluids of an infected person, or interaction with contaminated materials. Though less contagious than smallpox, monkeypox outbreaks have caused significant public health challenges due to their potential mortality and morbidity.

Monkeypox is closely related to the smallpox virus (variola virus), sharing numerous biological characteristics. Nonetheless, monkeypox generally presents milder symptoms and has lower fatality rates compared to smallpox. Despite the official eradication of smallpox in 1980, the cessation of smallpox vaccinations has resulted in a growing number of populations susceptible to other orthopoxviruses, including monkeypox.

Geographically, monkeypox virus is endemic to rainforest regions notably in Central and West Africa, where it has a higher infection rate among people who come into contact with wildlife. In recent years, cases have also been identified outside African regions, brought about by global travel and importation of animals. Countries such as the United States witnessed their first cases in 2003 through the importation of infected animals. Since the clinical presentation of monkeypox can be quite similar to other poxvirus infections, understanding its origins, transmission and geographical prevalence is essential for effective diagnosis, management, and prevention strategies.

How Monkeypox Virus Spreads

The monkeypox virus is a zoonotic pathogen, meaning it transmits from animals to humans. Initially identified in laboratory monkeys in 1958, monkeypox can be found in various animal species, predominantly rodents, and primates. Animal-to-human transmission primarily occurs through direct contact with the blood, bodily fluids, or lesions of infected animals. Additionally, consuming undercooked meat or other products derived from infected animals can lead to infection.

Human-to-human transmission of the monkeypox virus, though less common, also plays a significant role in its spread. Close contact with an infected person can lead to transmission via respiratory droplets, which are expelled when an infected person coughs or sneezes. This mode of transmission typically requires prolonged face-to-face interaction, making it a concern in healthcare settings or households where individuals are in close quarters.

Contaminated materials, such as clothing, bedding, or medical instruments, can also facilitate the transmission of the monkeypox virus. These items can retain the virus and serve as a source of infection if handled improperly. Ensuring proper sanitation and avoiding direct contact with such materials is crucial in preventing the spread of the virus.

It is important to note that while the virus can spread through these various routes, effective public health measures, including the isolation of infected individuals, proper hygiene practices, and the use of personal protective equipment (PPE), can significantly mitigate the risk of transmission. Understanding and adhering to these measures is vital in controlling outbreaks and protecting public health.

Recognizing Early Symptoms of Monkeypox

Monkeypox, a zoonotic viral infection, presents initial symptoms that often mimic those of more common illnesses, making early detection challenging yet crucial. Recognizing these early symptoms can be pivotal in managing the spread and ensuring timely treatment. One of the foremost signs is the sudden onset of fever. This fever can be considerably high and is typically the first indication that the body is combating an infection.

Accompanying the fever, individuals may experience severe headaches. These headaches can range from persistent, dull aches to more intense, throbbing sensations. Muscle aches, often referred to as myalgia, are another early symptom. These aches affect various muscle groups and can cause substantial discomfort, impacting the individual’s overall capability in daily activities.

Swollen lymph nodes, or lymphadenopathy, is a distinctive early symptom of monkeypox that helps differentiate it from other similar viral infections. These swollen glands can be tender to the touch and may appear in multiple regions of the body, including the neck, under the arms, and in the groin area. The swelling occurs as the body’s immune system reacts to the viral infection.

It is essential to understand that these early monkeypox symptoms can often be mistaken for other infectious diseases such as influenza, chickenpox, or measles, which exhibit similar initial signs. This overlap emphasizes the importance of keen observation and, if symptoms persist or worsen, seeking medical consultation promptly. Early detection is imperative for effective disease management and curbing further transmission. By recognizing and understanding the early signs of monkeypox, individuals and healthcare professionals can play a significant role in controlling outbreaks and minimizing the impact on affected populations.

Progressive Signs and Severe Symptoms

Upon the onset of early symptoms, the clinical presentation of monkeypox advances through several stages. The hallmark feature of monkeypox infection is the distinctive rash that emerges approximately one to four days following the initial fever and other early signs. Typically, the rash begins on the face before disseminating to other parts of the body including the palms, soles, and mucous membranes.

The rash progresses through several distinct stages. Initially, it appears as macules, which are flat, discolored spots on the skin. These macules then develop into papules, raised bumps that can be felt as firm areas on the skin. The next stage is the formation of vesicles, which are small fluid-filled blisters. These vesicles often evolve into pustules filled with pus, indicating infection and inflammation. Over the course of two to three weeks, the pustules eventually crust over, forming scabs that later detach and fall off. The entire rash cycle from macules to scabs typically spans around two to four weeks.

While most monkeypox cases are mild and self-limiting, some individuals may experience severe complications. Potential severe complications include secondary bacterial infections, bronchopneumonia, sepsis, encephalitis, and corneal infection, which can lead to vision impairment. Certain populations, such as individuals with weakened immune systems, children, and pregnant women, are at an elevated risk for these severe outcomes. It is crucial for healthcare providers to closely monitor patients for signs of complications, providing adequate supportive care and potential interventions when necessary.

Diagnosing Monkeypox

Accurate diagnosis of monkeypox is crucial for effective patient management and preventing further spread. Healthcare professionals employ a combination of clinical evaluations and laboratory tests to establish a diagnosis. The initial clinical evaluation involves a thorough examination of the patient’s symptoms. Common symptoms of monkeypox include fever, intense headache, swollen lymph nodes, and a characteristic rash that progresses through several stages—from macules to pustules—before forming scabs and eventually healing.

Given that the symptoms of monkeypox can resemble those of other diseases such as chickenpox or smallpox, distinguishing between them is essential. Chickenpox generally presents with a rash that appears in successive crops, while smallpox lesions are usually found at the same stage of development across the body. The presence of swollen lymph nodes (lymphadenopathy) is a key feature that differentiates monkeypox from smallpox.

Laboratory tests augment the clinical evaluation to confirm the diagnosis of monkeypox. One of the most definitive methods is polymerase chain reaction (PCR) testing, conducted on samples from skin lesion fluid, dry crusts, or swabs from the oropharynx. PCR assays can detect the presence of monkeypox DNA, providing concrete evidence of the virus. Serological tests to detect monkeypox-specific antibodies can also aid in the diagnosis, particularly in distinguishing it from other orthopoxvirus infections.

In addition to these tests, electron microscopy and cell culture methods, though less commonly used, can isolate and identify the virus from clinical specimens. It’s important to note that these methods require specialized laboratory settings and expertise.

The role of healthcare professionals extends beyond diagnostic testing to include the careful collection of patient history and a detailed physical examination. This information is vital for identifying potential sources of infection and assessing the severity of the disease. Early and accurate diagnosis is not only imperative for patient care but also for implementing control measures to contain the spread of monkeypox within communities.

Treatment Options for Monkeypox

Addressing monkeypox requires a multifaceted approach, primarily centered around supportive care. For most patients, supportive care is fundamental in managing the symptoms and improving quality of life during infection. This includes maintaining adequate hydration, using analgesics for pain relief, and antipyretics to control fever. Ensuring nutritional support and monitoring for potential secondary bacterial infections are further aspects of supportive care that are essential to treatment.

Antiviral medications have also become an integral part of the treatment regime for monkeypox. Tecovirimat, known by its brand name TPOXX, has shown promising results. This antiviral agent targets orthopoxviruses, which include the monkeypox virus. Studies indicate that tecovirimat can effectively reduce viral replication and severity of the disease when administered during the early stages of infection. Although it is not a cure, tecovirimat helps in shortening the duration of symptoms and potentially decreases the risk of complications.

Alongside direct treatment efforts, vaccination plays a vital role in preventing and controlling monkeypox outbreaks. The use of the smallpox vaccine, which offers cross-protection against monkeypox due to the genetic similarities between the viruses, has been revisited. The newer generation smallpox vaccine, JYNNEOS (also known as Imvamune or Imvanex), has been approved for monkeypox prevention. It is especially recommended for healthcare workers and those who have been in contact with confirmed cases.

Preventive measures extend beyond vaccination and involve public health strategies aimed at controlling the spread of monkeypox. Isolation of infected individuals, contact tracing, and educating communities about the transmission routes and symptoms of monkeypox are crucial during outbreaks. There is also a focus on strengthening health infrastructures to ensure rapid response capabilities and adequate resources to manage potential epidemics.

Preventative Measures and Vaccination

Reducing the risk of monkeypox virus infection requires a multi-pronged approach that combines individual hygiene practices, community health initiatives, and vaccination efforts. One of the primary preventative measures is the adherence to proper hygiene practices, particularly regular handwashing with soap and water. It is crucial to wash hands thoroughly after contact with animals or potentially contaminated surfaces to minimize the risk of virus transmission.

In addition to hand hygiene, safe handling of animals is imperative. Individuals should avoid handling wild animals, especially those that appear sick, as animals such as rodents can be reservoirs of the virus. When dealing with animals, whether in a domestic or professional setting, using protective equipment such as gloves and masks can offer additional layers of protection against the virus.

Another key preventative strategy is to limit direct contact with individuals infected with the monkeypox virus. Ensuring that those who are infected are isolated and receive appropriate medical care can help prevent the virus from spreading. It is also recommended to avoid sharing personal items with infected people and to disinfect surfaces that may have come into contact with the virus.

Vaccination plays a significant role in preventing monkeypox infections. Historically, smallpox vaccines have demonstrated some degree of protection against monkeypox due to the related nature of the viruses. While the routine administration of smallpox vaccines ceased after the eradication of smallpox, ongoing research has paved the way for developing more targeted vaccines for monkeypox. Recent advancements have led to the deployment of new-generation vaccines that show promise in providing effective protection against monkeypox.

Continued research and surveillance are essential to developing comprehensive preventative strategies and ensuring vaccines are readily available to at-risk populations. By embracing a combination of proper hygiene, safe animal handling, limiting contact with infected individuals, and vaccination efforts, communities can significantly mitigate the spread of the monkeypox virus.

Global Epidemiology and Public Health Response

Monkeypox, a zoonotic viral disease caused by the Monkeypox virus, has experienced varying incidence rates across different regions worldwide. Historically confined to West and Central African nations, significant outbreaks have been documented meticulously by global health organizations. Notably, the Democratic Republic of the Congo has persistently recorded the highest number of cases, emphasizing the endemic nature of the virus in certain tropical rainforests.

The global epidemiology of monkeypox witnessed a pivotal moment in 2003 when the virus appeared outside Africa, leading to an outbreak in the United States. More recently, smaller outbreaks have been observed in the United Kingdom, Israel, and Singapore, marking its sporadic nature and the potential for international transmission. Surveillance and reporting by entities such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) play a crucial role in tracking these patterns.

The WHO and CDC promptly respond to monkeypox outbreaks by initiating extensive monitoring and implementing control measures. These agencies issue travel advisories to inform travelers about potential risks, aiming to curtail the cross-border spread of the virus. Public health responses involve coordinated efforts including community education, vaccination programs, and the use of quarantine measures to manage the containment effectively.

Containment strategies are often tailored to the specific nature of outbreaks. For instance, raising awareness about avoiding contact with wildlife and infected humans, enhancing diagnostic capabilities, and establishing protocols for isolating confirmed cases are essential. Health agencies also work with local governments to ensure the dissemination of accurate information and resources to affected communities. The collective global endeavor to manage monkeypox relies on robust surveillance systems, international collaboration, and agile public health strategies to mitigate virus propagation and protect public health.